摘要
为了观察FOLFIRI方案治疗复治性晚期胃癌的临床疗效和毒副反应,对26例晚期复治性胃癌患者,采用FOLFIRI方案治疗。FOLFIRI方案:伊立替康180mg/m2,持续静脉滴入90min,d1;甲酰四氢叶酸400mg/m2,持续静脉滴入2h,d1;5-氟尿嘧啶400mg/m2,静脉推注,5-氟尿嘧啶2400mg/m2,静脉微量泵46h持续滴入,d1,14d为1个周期。连用4个周期后评价疗效。结果26例患者均可评价疗效与毒副反应,获得CR1例(3·8%),PR10例(38·5%),SD12例(46·2%),PD5例(11·5%),近期客观有效率为42·3%(11/26)。中位肿瘤进展时间(TTP)4·5个月,中位生存期为8·3个月。毒副反应主要为骨髓抑制、迟发性腹泻。初步研究结果提示,对于晚期复治性胃癌患者,FOLFIRI方案是一种有效的、不良反应可以耐受的治疗手段,值得进一步研究。
The objective of this study was evaluate the efficacy and toxicity of FOLFIRI regimen in the treatment of relapsed advanced gastric cancer. Twenty-six cases received FOLFIRI regimen. FOLFIRI regimen： CPT-11 180 mg/m^2 iv gtt 90 minutes d1 ,CF 400 mg/m^2 iv gtt 2 hours d1 , followed by 5-FU 400 mg/m^2 iv and 2 400 mg/m^2 using an ambulatory pump continuous infusion for 46 hours,and 14 days as one cycle. The efficacy was evaluated after 4 cycles. All the 26 cases were available for objective response. One patients achieved complete response （CR）, 10 patients partial response （PR）, 12 patients and stable disease （SD） ,and 5 patients progression disease （PD）. The overall response rate was 42. 3 % （11/26）. The median time to progression and overall survival was 4. 5 and 8. 3 months. CBR was 61.5 %. The main toxicities were myelosuppression and tardive diarrhoea. In conclusion, FOLFIRI regimen is effective and well tolerable in the treatment of relapsed advanced gastric cancer, and is worth to be used and researched widely.
出处
《中华肿瘤防治杂志》
CAS
2008年第7期544-545,共2页
Chinese Journal of Cancer Prevention and Treatment
